Stocks · News reference

ImmunityBio shares are trading lower after the company reported a wider GAAP net loss for the second quarter reflecting a sharp increase in expenses.

Aug 4, 2026, 3:04 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 19, 2026, 4:15 PMBenzinga News-desk
Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.
BNTX IBRX MRVI PFE SLS
BenzingaAug 4, 2026, 11:41 AMBenzinga Newsdesk
ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10) per share from the
IBRX
SEC EDGARAug 4, 2026, 11:36 AMSEC EDGAR
8-K filing — ImmunityBio, Inc. (IBRX)
Filed: 2026-08-04 AccNo: 0001326110-26-000077 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
IBRX